Skip to main content

Table 4 DHP treatment by demographic factors

From: Risk factors for non-participation in ivermectin and dihydroartemisinin-piperaquine mass drug administration for malaria control in the MASSIV trial

 

Total population (N = 3311)

Eligible population/total population (%)

Eligible Population for DHP (N = 3290)

No MDA complete (%)

1 month of MDA complete (%)

2 months of MDA complete (%)

3 months of MDA complete (%)

Total

3290/3311 (99.4)

422 (12.8)

380 (11.6)

623 (18.9)

1865 (56.7)

Houshold Head MDA

 Complete

1742/1754 (99.3)

191 (10.9)

162 (9.3)

281 (16.1)

1108 (63.6)

 Incomplete

999/1006 (99.3)

128 (12.8)

155 (15.5)

240 (24)

476 (47.7)

 None

549/551 (99.6)

103 (18.8)

63 (11.4)

102 (18.6)

281 (51.2)

Agegroup

  < 5 years

564/585 (96.4)

47 (8.3)

51 (9)

104 (18.4)

362 (64.2)

 5–15 years

1065/1065 (100)

65 (6.1)

69 (6.5)

167 (15.7)

764 (71.7)

  > 15– 25 years

543/543 (100)

117 (21.6)

92 (16.9)

127 (23.4)

207 (38.1)

  > 25–50

780/780 (100)

145 (18.6)

121 (15.5)

159 (20.4)

355 (45.5)

  > 50 years

338/338 (100)

48 (14.2)

47 (13.9)

66 (19.5)

177 (52.4)

Sex

 Female

1768/1780 (99.3)

230 (13)

225 (12.7)

332 (18.8)

981 (55.5)

 Male

1522/1531 (99.4)

192 (12.6)

155 (10.2)

291 (19.1)

884 (58.1)

Ethnicity

 Fula

2062/2065 (99.9)

88 (4.3)

228 (11.1)

425 (20.6)

1321 (64.1)

 Mandinka

637/638 (99.8)

30 (4.7)

49 (7.7)

108 (16.9)

450 (70.7)

 Sarahule

134/134 (100)

6 (4.5)

12 (8.9)

25 (18.7)

91 (67.9)

 Wollof

3/3 (100)

0 (0)

0 (0)

0 (0)

3 (100)

 Not specified

454/471 (96.4)

298 (65.6)

91 (20)

65 (14.3)

0 (0)

Household size

  < 6

51/51 (100)

6 (11.8)

5 (9.8)

11 (21.6)

29 (56.8)

 6–11

390/391 (99.7)

48 (12.3)

60 (15.4)

75 (19.2)

207 (53)

 12–24

1365/1373 (99.4)

163 (11.9)

144 (10.6)

236 (17.3)

822 (60.2)

 25–50

1136/1141 (99.5)

149 (13.1)

121 (10.7)

219 (19.3)

647 (56.9)

  > 50

348/355 (98)

56 (16.1)

50 (14.4)

82 (23.6)

160 (45.9)